Fig. 2From: Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practiceCentral macular thickness (CMT) of the ranibizumab (RBZ) poor-responder patients after the 3rd injection with RBZ (mean: 320.00 ± 82.05 μm) and after the 3rd injection with aflibercept (AFL) (mean: 282.27 ± 56.86 μm)Back to article page